Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

He TC, Chan TA, Vogelstein B, Kinzler KW.

Cell. 1999 Oct 29;99(3):335-45.


Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.

Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, Pals ST.

Br J Cancer. 2004 Jan 12;90(1):224-9.


Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells.

Park BH, Vogelstein B, Kinzler KW.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603.


Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells.

Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ.

Mol Cancer Ther. 2003 Sep;2(9):885-92.


The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling.

Dihlmann S, Siermann A, von Knebel Doeberitz M.

Oncogene. 2001 Feb 1;20(5):645-53.


Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

Orner GA, Dashwood WM, Blum CA, Díaz GD, Li Q, Al-Fageeh M, Tebbutt N, Heath JK, Ernst M, Dashwood RH.

Mutat Res. 2002 Sep 30;506-507:121-7.


Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW.

Science. 1997 Mar 21;275(5307):1787-90.


Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac.

Orner GA, Dashwood WM, Blum CA, Díaz GD, Li Q, Dashwood RH.

Carcinogenesis. 2003 Feb;24(2):263-7.


Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H.

Science. 1997 Mar 21;275(5307):1784-7.


A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics.

Wakita K, Tetsu O, McCormick F.

Cancer Res. 2001 Feb 1;61(3):854-8.


A nuclear receptor to prevent colon cancer.

Wu GD.

N Engl J Med. 2000 Mar 2;342(9):651-3. Review. No abstract available.


Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation.

Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S.

Cancer Res. 2001 Mar 15;61(6):2751-8.


Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac.

Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM.

Cancer Res. 1999 Jan 15;59(2):353-9.


Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells.

Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA.

Carcinogenesis. 2002 Jan;23(1):107-14.


Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis.

Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC.

J Clin Invest. 2000 Aug;106(4):533-9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk